English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Beyond the diagnosis of SARS-CoV-2 infection, tools delivering a global picture of the patients’ humoral response may be of interest for the comprehension of the disease severity and the assessment of the patients’ protection for vaccination strategy.  Objectives: Here we use a commercial multiplex serological immunoassay CoViDiag®, based on an array of five different antigens of the virus (the Nucleocapsid, the Spike 1 and Spike 2 subunits, and the RBD and NTD domains of the Spike), to investigate the profile of the IgG humoral response for patients with recent SARS-CoV-2 infection depending on the disease severity outcome, or the time post-PCR.  Results: No cross-reaction was observed with the four other seasonal coronaviruses (100% specificity, 0/28). 100% (20/20) of the hospitalized patients PCR-positive to SARS-CoV-2 presented detectable levels of IgGs. 14 days post-PCR diagnosis, 92.3% of the patients, PCR-positive, that did not required hospitalization are presenting IgG (36/39). Interestingly for CoViDiag-positive samples, detectable levels of anti-RBD were found mainly in hospitalized patients (85%, 17/20), while the presence of anti-S1 (60.9%, 28/46) combined with the absence of anti-RBD (6.5%, 3/46) was more characteristic of nonhospitalized patients. Screening campaign group lacked both anti-S1 (18.2%, 4/22) and anti-RBD (4.5%, 1/22).  Conclusion: The CoViDiag® IgG assay could be used to evaluate patients’ immunization and improve their management.

Determination of IgG Response Profile in SARS-CoV-2 Patients Using a Multiplex Serological Assay